GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » icad Inc (NAS:ICAD) » Definitions » Net Change in Cash

icad (ICAD) Net Change in Cash : $-1.43 Mil (TTM As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is icad Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

icad's Net Change in Cash for the three months ended in Mar. 2024 was $-1.39 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.43 Mil.

icad Net Change in Cash Historical Data

The historical data trend for icad's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

icad Net Change in Cash Chart

icad Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.13 11.87 7.10 -12.97 0.36

icad Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.65 -0.63 -1.91 2.50 -1.39

icad Net Change in Cash Calculation

icad's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-4.964+3.275+2.046+0
=0.36

icad's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.18+-0.206+0+0
=-1.39

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

icad Net Change in Cash Related Terms

Thank you for viewing the detailed overview of icad's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

icad (ICAD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » icad Inc (NAS:ICAD) » Definitions » Net Change in Cash
Comparable Companies
LFWD RPID LNSR CUTR CODX ECOR CTSO LUCD IINN MDAI ABT SYK BSX MDT XTER:SHL EW SZSE:300760 DXCM ZBH ALGN
Traded in Other Exchanges
N/A
Address
98 Spit Brook Road, Suite 100, Nashua, NH, USA, 03062
Website
https://www.icadmed.com
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.
Executives
Eric Lonnqvist officer: See Remarks 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 02062
Daniel Joseph Shea officer: See Remarks 2 MINUTEMAN ROAD, MEDFIELD MA 02052
Jonathan Go officer: Sr. VP of R&D C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Stephen P Sarno officer: See Remarks C/O SAPIENT CORPORATION, 25 FIRST STREET, CAMBRIDGE MA 02141
Andy Sassine director 82 DEVONSHIRE STREET, BOSTON MA 02109
Dana R Brown director 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Timothy Norris Irish director 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Nathaniel Dalton director C/O AFFILIATED MANAGERS GROUP INC, 777 S. FLAGLER DR., SUITE 1201 E. TOWER, WEST PALM BEACH FL 33401
Susan Alyson Wood director 845 MORENO AVENUE, PALO ALTO CA 94303
Michael S Klein director C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Charles Ross Carter officer: See Remarks C/O GI DYNAMICS, INC., 745 ATLANTIC AVENUE, BOSTON MA 02111
Stacey M Stevens officer: Executive VP of Marketing C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
R. Scott Areglado officer: Interim Chief FinancialOfficer 98 SPIT BROOK ROAD, SUITE 100, C/O ICAD, INC., NASHUA NH 03062
Rakesh Patel director 15400 NATIONAL AVENUE, LOS GATOS CA 95032
Dr Lawrence Howard director C/O PRESSTEK INC, 2 GREENWICH OFFICE PARK, GREENWICH CT 06831